Celluminova specializes in the development of new tools for stem cell research, including cancer stem cells. The patented biomarker GlioStem is intended for the detection and visualization of stem cell-like cells in brain tumors. Today, there are no products on the market that target stem cell-like cells in these tumors. The goal of the product is for it to be used during operations to completely remove tumor tissue and thereby partly increase patient survival and partly quality of life. Celluminova has its origins in the technical and medical faculty and the IFM department at Linköping University.